Stroke Trials

What are the complication rates of carotid artery stenting (CAS) when performed by fellowship-trained neurointerventionalists (NIRs)?

Does targeted training of the ipsilesional (less impaired) arm improve motor performance in chronic stroke patients with severe contralesional arm paresis?

Does a BCI intervention using the ReHand-BCI system with robotic hand orthosis feedback produce greater upper extremity motor recovery and neuroplastic changes compared to a sham-BCI intervention in stroke patients with hand paresis?

What are the long-term effects (through 12 months) of vagus nerve stimulation (VNS) paired with rehabilitation on impairment, activity, and participation in people with upper extremity (UE) impairment after chronic ischemic stroke?

Can cervical epidural spinal cord stimulation safely and effectively improve motor function and reduce spasticity in individuals with chronic post-stroke upper-limb hemiparesis?

In patients with acute ischemic stroke undergoing endovascular thrombectomy under general anesthesia, does early extubation (<6 hours) improve 90-day functional outcomes compared with delayed extubation (6-12 hours)?

Does glenzocimab, a platelet GPVI antagonist, improve functional outcomes when added to IV thrombolysis (± thrombectomy) in acute ischemic stroke?

Among patients with acute ischemic stroke without large or medium vessel occlusion or a cardioembolic source, does IV tirofiban after an insufficient response to IV tenecteplase improve functional outcomes?

Is intravenous recombinant human prourokinase non-inferior to alteplase for achieving excellent functional outcome in patients with acute ischaemic stroke who are ineligible for or refuse endovascular thrombectomy?

Does adding intravenous tenecteplase before thrombectomy improve functional independence at 90 days in patients with acute ischemic stroke due to large-vessel occlusion?

Is tenecteplase effective and safe for patients with ischemic stroke due to large/medium vessel occlusion within 4.5–24 hours of last known well using perfusion imaging selection?

In patients with acute LVO stroke without atrial fibrillation or intracardiac thrombus, which cardiac CT findings are independently associated with a cardioembolic stroke aetiology?

Does loberamisal, a dual-acting neuroprotective agent, improve functional recovery when administered within 48 hours of moderate to severe acute ischemic stroke?

Does minocycline, in addition to routine treatment, improve 90-day functional outcomes compared with placebo in patients with acute ischaemic stroke presenting within 72 hours of symptom onset?

Does middle meningeal artery (MMA) embolization reduce the rate of chronic subdural hematoma (CSDH) recurrence in patients who underwent an operation and are at high risk of recurrence?

Can rivaroxaban prevent cognitive decline in AF patients too low-risk for standard anticoagulation?

Does staged bilateral MRgFUS thalamotomy provide meaningful and sustained tremor reduction — including midline tremor — with an acceptable safety profile in essential tremor patients who previously underwent unilateral treatment?

Does peri-procedural subcutaneous semaglutide improve 90-day functional outcomes when added to endovascular thrombectomy in patients with acute LVO stroke who have not received intravenous thrombolysis?

Are direct oral anticoagulants (DOACs) as safe and effective as vitamin K antagonists (VKAs) for the treatment of cerebral venous thrombosis?

Among patients with asymptomatic high-grade carotid stenosis, does adding carotid revascularization (stenting or endarterectomy) to intensive medical management provide greater benefit than intensive medical management alone in preventing stroke?

Does revascularization reduce stroke risk when added to optimized medical therapy in patients with asymptomatic or low-to-intermediate risk symptomatic carotid stenosis?

To determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis (IVT), and conservative standard therapy (CST) on visual outcomes in nonarteritic central retinal artery occlusion (CRAO).

Does tirzepatide improve obstructive sleep apnea severity and associated complications in adults with moderate-to-severe OSA and obesity?

What are the new clinical (ischemic stroke, intracranial/major extracranial bleeding, or death) and new MR-Imaging outcomes (ischemic or hemorrhagic brain lesions) between 3 and 6 months in patients with symptomatic, MR-imaging-verified cervical artery dissection treated with aspirin versus anticoagulation?

To compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation regarding stroke prevention and major hemorrhage.

Can a simple clinical score predict which ESUS patients will develop atrial fibrillation on long-term implantable cardiac monitoring?

Can the PASCAL classification system identify which patients with PFO and cryptogenic stroke will experience net benefit versus net harm from transcatheter PFO closure?

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation?

Can left atrial appendage closure replace NOACs for stroke prevention in anticoagulation-eligible AF patients?

Does adding catheter ablation to standard edoxaban therapy reduce the risk of recurrent ischemic stroke or composite cardiovascular outcomes in patients with nonvalvular atrial fibrillation and a recent history of ischemic stroke?

In the MT era, in-hospital stroke continues to present with greater neurological severity, longer recognition-to-imaging times, and substantially worse in-hospital outcomes than community-onset stroke...

Is IV tenecteplase plus endovascular thrombectomy (TNK + EVT) associated with better 3-month functional outcomes compared with EVT alone in patients with anterior circulation LVO stroke treated within 4.5 hours, and does any benefit vary with expected onset-to-thrombolysis time or admission center type?

In patients with recent noncardioembolic ischemic stroke or high-risk TIA on antiplatelet therapy, does asundexian 50 mg once daily (an activated factor XI inhibitor) reduce the risk of recurrent stroke compared with placebo?

Among patients with atherosclerotic cardiovascular disease, is targeting an LDL cholesterol level of less than 55 mg per deciliter superior to targeting a level of less than 70 mg per deciliter for preventing recurrent major cardiovascular events?

Does endovascular thrombectomy improve functional outcomes in patients with medium-vessel occlusion strokes and moderate-to-severe deficits?

Does intra-arterial tenecteplase after successful thrombectomy improve clinical outcomes in patients with acute large vessel occlusion presenting between 4.5 and 24 hours after symptom onset?

Is 0° head positioning superior to 30° head positioning at maintaining clinical stability in patients with large vessel occlusion stroke who are candidates for thrombectomy?

Does emergent carotid stenting (eCAS) during endovascular thrombectomy (EVT) for anterior circulation tandem lesions improve 90-day functional outcomes compared with a no-stenting strategy?

Does intensive systolic blood pressure reduction below 130–140 mmHg after successful mechanical thrombectomy improve functional outcomes compared to standard blood pressure management in acute ischemic stroke?

Does lepodisiran, an siRNA targeting hepatic production of lipoprotein(a), safely and effectively reduce serum lipoprotein(a) concentrations over time?

Does clazosentan (15 mg/hour IV), an endothelin receptor antagonist, reduce clinical deterioration due to delayed cerebral ischemia when administered for up to 14 days alongside standard care (including nimodipine) in patients with aneurysmal subarachnoid hemorrhage and thick diffuse clot?

Does a liberal red-cell transfusion strategy, as compared with a restrictive strategy, result in a lower risk of an unfavorable neurologic outcome at 12 months in critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia?

Is galantamine safe, tolerable, and potentially efficacious in improving long-term functional and cognitive outcomes in patients with aneurysmal subarachnoid hemorrhage when administered during early and subacute stages?

Does middle meningeal artery embolisation (MMAe) reduce the composite of surgical drainage need, poor clinical outcome, or clinical deterioration compared to observation alone in mildly symptomatic chronic subdural haematoma patients?

Among patients with prior intracerebral hemorrhage, does a single pill combining three low-dose antihypertensive agents reduce recurrent stroke compared with placebo, when added to standard care?

Does recombinant factor VIIa given within 2 hours of ICH onset improve functional outcomes compared to placebo?

To compare the safety and efficacy of minimally invasive surgery with the Artemis Neuro Evacuation Device to guideline-based medical management alone for spontaneous supratentorial intracerebral hemorrhage (ICH).